Greenwich LifeSciences Boosts Cash Position with ATM Financing Amid Promising Phase III Trial Data — Greenwich LifeSciences, Inc.

Event summary

Greenwich LifeSciences raised more than its Q1 2026 cash burn rate via ATM financing, ending the quarter with $10.5M in cash.
FLAMINGO-01 Phase III trial's non-HLA-A*02 arm is fully enrolled, showing a 70-80% reduction in recurrence rates post-primary immunization series.
Over 1,000 patients screened for FLAMINGO-01 with current screen rate of ~800 patients per year.
Phase IIb trial results showed an 80%+ reduction in metastatic breast cancer recurrences over 5 years.

The big picture

Greenwich LifeSciences' strategic focus on immunotherapy for breast cancer prevention positions it within the growing oncology market targeting high-recurrence-risk patients. The company's ability to secure financing through ATM offerings while advancing its Phase III trial reflects both operational agility and investor confidence in its differentiated approach to HER2-positive breast cancer treatment.

What we're watching

Trial Execution: Whether the promising preliminary data from FLAMINGO-01's non-HLA-A*02 arm will translate into statistically significant results at study completion.
Financial Runway: The pace at which Greenwich LifeSciences can sustain its operations through ATM financings while awaiting potential regulatory approvals.
Market Differentiation: How GLSI-100's recurrence reduction rates will position it against existing therapies offering 20-50% reductions in breast cancer recurrences.